Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CEST

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
11:45a ASTRAZENECA : Targeted Drug for Lung Cancer Debuts China
11:22a ASTRAZENECA PLC (ADR) (NYSE : AZN) Tagrisso Wins Approval In China
09:25a Chinese drug approval boosts AstraZeneca's lung cancer hopes
08:15a ASTRAZENECA : Tagrisso approved in China as first-in-class treatment for EGFR T7..
03/25 ASTRAZENECA : s SGLT-2 Inhibitors Greatly Lowered Hospitalization Risks for HF P..
03/24 GLOBAL GASTROINTESTINAL DRUGS MARKET : Abbott Laboratories, Allergan, AstraZenec..
03/23 ASTRAZENECA : and Circassia to Develop COPD Inhalants
03/22 ASTRAZENECA : gets second CRL for Zs-9 after Zs Pharma plant inspection
03/21 ASTRAZENECA : CVD-REAL study shows SGLT-2 inhibitors significantly reduced death..
03/21 CIRCASSIA PHARMACEUTICALS : to acquire US rights to Tudorza and Duaklir from Ast..
More news
Sector news : Pharmaceuticals - NEC
08:03pDJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
05:37pDJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
04:16pDJEU Clears Dow-DuPont Deal With Conditions -- Update
09:25a Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:35p Doctors see no clear frontrunner in PARP race; TESARO down 2% on lack of lead..
12:36p AstraZeneca's Tagrisso OK'd in China to treat lung cancer
03/25 MARKETPLACE ROUNDTABLE : Biotech Hanging In The Balance
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/21 AstraZeneca's Mistakes Mount
Advertisement
Financials ($)
Sales 2017 21 453 M
EBIT 2017 5 750 M
Net income 2017 2 658 M
Debt 2017 12 189 M
Yield 2017 4,49%
P/E ratio 2017 29,41
P/E ratio 2018 22,91
EV / Sales 2017 4,19x
EV / Sales 2018 4,05x
Capitalization 77 756 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 63,5 $
Spread / Average Target 3,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC11.06%78 074
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results